Jerusalem Pharmaceuticals Co. Ltd. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2018
Jerusalem Pharmaceuticals Co. Ltd. announced unaudited consolidated earnings results for the first quarter ended March 31, 2018. For the quarter, the company reported net income after tax of $1,188,800 or $0.066 per basic and diluted share compared to net income after tax of $1,605,998 or $0.089 per basic and diluted share reported in the same period last year. Sales were $8,418,052 against $8,406,019 reported last year. Net Income before tax was $1,190,386 against $1,607,756 reported last year. Net cash flow from operating activities was $879,656 against $1,629,424 reported last year. Purchase of property, plant and equipment was $239,841 against $693,716 reported last year. Purchase of intangible assets was $108,868.